Mpox (Monkeypox) Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Mpox (Monkeypox) Infection Market Outlook
Thelansis’s “Mpox (Monkeypox)
Infection Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Mpox (Monkeypox) Infection
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Mpox (Monkeypox) Infection Overview
Monkeypox
is a zoonotic disease historically endemic to West and Central Africa, caused
by the monkeypox virus (MPXV). This virus belongs to the Orthopoxvirus (OPV)
genus within the Poxviridae family, which also includes the variola virus
(VARV, or smallpox), vaccinia virus (VACV), camelpox virus (CMPV), and cowpox
virus (CPXV), all of which are pathogenic to humans. The monkeypox virus is
characterized by double-stranded DNA (dsDNA) and exhibits a brick-like
morphology with particles measuring 200–250 nm in diameter. Two genetic clades
of MPXV have been identified: the West African (WA, Clade II) clade and the
Congo Basin (CB, Clade I) clade, the latter also known as the Central African
(CA) clade, which is associated with more severe disease. Polymerase chain
reaction (PCR) is the preferred method for detecting MPXV DNA. When feasible,
optimal diagnostic specimens are collected from the rash, including skin,
fluid, crusts, or biopsy samples. Antigen and antibody detection methods may be
less useful as they must differentiate between orthopoxviruses. There is
limited comprehensive data on the pathophysiology and treatment of monkeypox.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations
for target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment